Skip to main content
TipRanks
Go Ultimate75% OFF

Daniel Raynor Insider Profile

4 Followers

Daniel Raynor, Director at ANI Pharmaceuticals, holds 289.00K shares in ANI Pharmaceuticals (Ticker: ANIP). Most recently, Daniel Raynor Sold 7,215 shares of ANI Pharmaceuticals on Mar 19, 2018 for an estimated value of $439.05K.

Daniel Raynor's Trading History

ANIP
ANI Pharmaceuticals
Mar 19, 2018DirectorInformative Sell439.05K$20.65M
ANIP
Insider Shares: 289.00K (2.48%)
DateTransactionAmountNo. of SharesPrice per ShareProfitLink to Report
Mar 19, 2018Informative Sell$439.05K7,215$60.85-4.90%
Mar 14, 2018Informative Sell$1.74M27,964$62.24-2.70%
Apr 04, 2017Uninformative Buy$0.001,000$0.00―
Apr 11, 2016Uninformative Buy$0.001,000$0.00―
Apr 20, 2015Uninformative Buy$0.00800$0.00―

You May Also Like

Daniel Raynor insider profile FAQ

What is the percentage of profitable transactions made by Daniel Raynor?
The percentage of profitable transactions made by Daniel Raynor is 20%.
What is the average return per transaction made by Daniel Raynor?
The average return per transaction made by Daniel Raynor is -24.80%.
What stocks does Daniel Raynor hold?
Daniel Raynor holds: ANIP stocks.
What was Daniel Raynor’s latest transaction?
Daniel Raynor’s latest transaction was an Informative Sell of $439.05K.
What was Daniel Raynor's most profitable transaction?
Daniel Raynor’s most profitable transaction was an Informative Sell of ANIP stock on March 16, 2015. The return on the trade was 50.00%.
What is Daniel Raynor's role in ANI Pharmaceuticals?
Daniel Raynor's role in ANI Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.